Supportive care in patients with acute leukaemia: historical perspectives.

Review Supportive care in patients with acute leukaemia: historical perspectives Giovanna Cannas1, Xavier Thomas2 Haemovigilance Unit, Edouard Herriot Hospital and Croix-Rousse Hospital, Hospices Civils de Lyon; 2Leukaemia Unit, Haematology Department, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France

1

iz

iS rl

Prior to 1954, blood transfusions were performed with rubber tubes and glass bottles. Progress in technologies and materials led to significant improvements. The development of plastic phlebotomy equipment has made the procedure of plasmapheresis feasible as an alternate form of blood donation. A platelet replacement programme initiated in children with leukaemia in 1958 demonstrated that platelets had an effect on haemorrhages and mortality. In this brief historical review, we examine the major advances in the history of blood transfusion and the impact of transfusions on the treatment of acute leukaemia. Targeted more specifically at the young haematologist and the general educated reader, this review aims to communicate accounts of scientific and medical discovery and practice in this domain. It relies upon chronology as an organising framework, while stressing the importance of themes.

Se

Although most treatments for leukaemia were ineffective until the middle of the 20th century, it seemed of interest to review some pertinent examples of the evolution of supportive care from its origin to its current use in this disease. Indeed, patients with leukaemia often have associated life-threatening disorders such as severe anaemia, bleeding or serious infections, and improvements in the management of these complications has totally transformed the outcome of the underlying disease. Modern therapy of acute leukaemia began in the 1960s. The major development in the treatment of acute leukaemia came from St. Jude Children's Research Hospital in Memphis, with Don Pinkel introducing a four-phase treatment plan for acute lymphoblastic leukaemia, which he called "total therapy" 1. The principles that were applied took into account the advantage of combination chemotherapy in overcoming initial drug resistance and inhibiting acquired resistance, as well as the superiority of some drugs for inducing remissions and others for maintaining the remissions. All available antileukaemic agents were incorporated into the plan, including vincristine and prednisone as induction therapy, 6-mercaptopurine and methotrexate for maintenance chemotherapy, and then radiotherapy to the central nervous system to prevent meningeal relapse. This schedule resulted in a tremendous increase in the survival rate of children with acute lymphoblastic leukaemia with more than 50% becoming long-term survivors. Concomitantly to the development of more intensive chemotherapies, the need for supportive care increased. Leukaemia and its treatment can cause a number of complications and side effects. Patients receive supportive care to prevent or control these problems and to improve their comfort and quality of life during the leukaemia treatment. Advances in the control of infections and bleeding have been major factors in the improved outcome of leukaemia therapy. Blood transfusions are an important part of haematological care: transfusions of red blood cells may be used to reduce the symptoms of anaemia and platelet transfusions to reduce the risk of serious bleeding. Transfusions have long been associated with some risk to patients. Blood transfusion technology advanced rapidly during World War II, leading to national systems of blood banks.

rv

Introduction

Blood transfusions

©

SI M

TI

Blood transfusions represent one of the most important forms of supportive care for patients with leukaemia. Cancer is the major cause of transfusion. One third of transfused patients have a malignant disease, with acute leukaemia being the malignancy in a large part of them. More than 50% of transfused blood products are used in this setting. While the first case of blood transfusion to a patient with leukaemia was carried out in 18732, it was not until 1900 that the most important advance towards safe and effective transfusion took place with the discovery of the human blood groups3. However, blood transfusion had a long history in medicine prior to the introduction of chemotherapy and the use of blood products as supportive care in the treatment of leukaemia. First successful transfusions After the first historical attempts at blood transfusion between animals4,5 or between animals and humans6, the technique of transfusion was developed through the 19th century, with alternating periods of enthusiasm and periods of frustration and discouragement (Table I). Blood transfusions came back to the fore with the Franco-Prussian War at the end of the century and the identification of the first blood groups at the beginning of the 20th century.

Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14 © SIMTI Servizi Srl

All rights reserved - For personal use only No other use without premission

205

Cannas G, Thomas X Table I - Milestones in transfusion medicine from the first successful transfusions to the modern era. Philip Sying Physik performed the first known human blood transfusion.

1816

John Henry Leacock established the principle that donor and recipient must be of the same species240.

1818

James Blundell performed the first documented transfusion of human blood241-243.

1853

Alexander Wood invented the hypodermic syringe, leading to the development of new devices to carry out transfusions244.

1865

Joseph Roussel first employed a direct arm-to-arm transfusion method245.

1870s

Period of enthusiasm for transfusion of blood substitutes (milk, ect. …), particularly in the USA246,247.

1870-71

Franco-Prussian War: use of blood transfusions on the battlefield.

1878

Georges Hayem perfected a saline solution, which can serve as a substitute of blood248.

1901

Karl Landsteiner documented the first three blood groups3.

1907

Ludwig Hektoen: improvement in safety of transfusion by cross-matching blood between donors and patients.

1907

Reuben Ottenberg performed the first blood transfusion using blood typing and cross-matching13,15.

1914-15

Albert Hustin, Luis Agote, Richard Lewisohn: use of sodium citrate that can be mixed to donor blood to prevent coagulation249-252.

1916

First blood transfusion using blood that has been stored and cooled after Francis Peyton Rous and J.R. Turner used a glucose additive to improve red cell preservation21.

1918

Oswald Robertson, a medical researcher and USA Army officer, established the first blood depot while serving during World War I23.

1921

Percy Lane Oliver, following a request from the Red Cross service, pioneered the voluntary blood donor scheme in London24.

1925

Alexander Bogdanov founded the first academic institution devoted to the science of blood transfusion in Moscow.

1927

Landsteiner and Levine proposed two new blood group systems: MN and P10,12.

1930

Charles R. Drew discovered that blood could be separated into plasma and red blood cells29.

1932

Serge Yudin established the first hospital blood depot in Leningrad25.

1936

During the Spanish Civil War, the development of electrical refrigeration resulted in the first blood banks set up by Federico Duran Jorda in Barcelona and Norman Bethune in Madrid253.

1936

Hyland marketed the first vacuum blood collection bottle.

1935

The long-term storage of plasma was facilitated by the process of lyophilisation developed by Flosdorf and Mudd254.

1937

Bernard Fantus established the first hospital blood bank of the USA, in Chicago26,27.

1939-40

Karl Landsteiner, Alexander Wiener, Philip Levine, and R.E. Stetson discovered the Rhesus blood group system18-20.

1941

Isidor Ravdin successfully used albumin in transfusions in victims of the Pearl Harbour attack.

1943

John Freeman Loutit and Patrick L. Mollison introduced acid-citrate dextrose (ACD) solution, which reduces the volume of anticoagulant32.

1944

Use of dried plasma in the treatment of wounded soldiers during World War II.

1944

Edwin Cohn developed cold ethanol fractionation, a process to break down plasma into its different fractions30,31.

1945

Robin Coombs, Arthur Mourant and Robert Race described the use of antihuman globulin to identify "incomplete" antibodies255.

1946

Kekwick, Mackay and Record produced fibrinogen and prothrombin from plasma separated by precipitation with ether256.

1947

Sanger and Race identified the S and s genes11.

1950

Carl Walter and W.P. Murphy introduced the plastic bag for blood collection257.

1950

Audrey Smith successfully froze red blood cells using glycerol cryoprotectant.

1952

Gibson demonstrated that plastic systems allowed removal of plasma after sedimentation and centrifugation258.

1958

Jean Dausset discovered the first human leucocyte antigen (HLA) on the surface of blood cells259.

1960

Alan Salomon and John L. Fahey developed plasmapheresis, a procedure for separating whole blood into plasma and red blood cells.

1969

Scott Murphy and Frank Gardner developed a method for storing platelets at room temperature69.

1971

The practice of testing donated blood for hepatitis B began.

1972

Apheresis, the process of separating out only plasma or one specific type of blood cell from donated blood, came into use.

1979

Introduction of CPDA-1, a new anticoagulant preservative, which increased the blood supply and facilitated resource-sharing among blood banks260.

1980s

Additive solutions extended the shelf-life of red blood cells to 49 days33.

1980s

The practice of testing donated blood for HIV began.

1999

The use of nucleic acid amplification testing for active viruses in donated blood was introduced.

©

SI M

TI

Se

rv

iz

iS rl

1795

Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14 206


Blood transfusion in leukaemia

rv

iz

iS rl

J.R. Turner, the first blood transfusion using blood that had been stored and cooled was performed in 1916. The first blood depot was established in France during World War I23. The Spanish Civil War also gave rise to a major initiative to increase the number of blood donors and to establish large-scale blood depots to ensure adequate supplies. This resulted in its introduction to civilian medical practice24. The first hospital blood depots were established by Serge Yudin in Russia in 193225, and by Bernard Fantus, who originated the term "Blood bank", in the USA in 193726. Within a few years, hospital and community blood banks were established across the USA and blood storage became widely practiced in the most important nations27. The International Society of Blood Transfusion (ISBT) was founded in 1935. With the prospect of World War II, the War Office made the decision to determine the blood group of every member of HM Forces and issued all medical units with the equipment required for transfusion. The Army Blood Transfusion Service was set up, as was an equipment depot - the Army Blood Supply Depot. After World War II, it was realised that the structure, which had proven successful for blood collection, should be preserved, leading to the creation of National Blood Transfusion Services28. The modern era Important developments in transfusion medicine have been achieved in the last 80 years. The main ones are summarised in Table I. Blood can be separated into plasma and red blood cells, and plasma can be frozen separately29. Plasma can also be broken down into its different fractions: fibrinogen, gamma globulin, and albumin30,31. This led to the production of novel blood products, including a durable substitute for liquid plasma. The development of plastics enabled the evolution of a collection system capable of safer and easier preparation of multiple blood components from a single unit of whole blood. In 1953, the development of the refrigerated centrifuge began to further expedite blood component therapy. The introduction of acid-citrate dextrose (ACD) solution reduced the volume of anticoagulant necessary and enabled transfusions of greater volumes and longer term storage32. Additive solutions extended the shelf-life of red blood cells to 49 days33. Technical progress by equipment manufacturers and the advent of computer-based technologies produced an avalanche of new equipment from the 1970s onwards, and many manual techniques and procedures became automated34-36. Up to the period just after World War II, virtually nothing could be done for patients with acute leukaemia37. Nitrogen mustards had been introduced as a by-product of World War I but were not effective

©

SI M

TI

Se

Identification of human blood types and groups In the latter part of the 19th century, physiologists demonstrated that blood from one species could destroy the cells of transfused subjects of another species. Similarly, blood cells from different individuals of the same species could agglutinate when mixed. In 1901, Karl Landsteiner, an Austrian physician, documented the first three blood groups, based on substances present on red blood cells, A, B and O3. The following year, Alfred von Decastello and Adriano Sturli defined a fourth group, AB7. Other blood types were described by Jansky in 19078 and by Moss in 19109. In 1927, Landsteiner and Levine proposed a new blood group system after the identification of two new genes, M and N10. The system was later extended after Sanger and Race identified the related S and s genes in 194711. Additionally, in 1927, Landsteiner and Levine discovered the P blood group system12. In 1907, Ludwig Hektoen suggested that the safety of transfusion might be improved by cross-matching blood between donors and patients to exclude incompatible mixtures. Reuben Ottenberg, who performed the first blood transfusion using blood typing and cross-matching at Mount Sinai Hospital in New York in 1907, also observed the "Mendelian inheritance" of blood groups and the "universal" utility of group O donors13-15. Despite these advances, transfusions continued to be performed without any preliminary "cross-agglutination" testing. In 1908, Alexis Carrel, a French surgeon, devised a way to prevent blood clotting. His method involved joining an artery in the donor, directly to a vein in the recipient with surgical sutures16. The Kimpton-Brown transfusion apparatus, consisting of a paraffin-coated gradient glass cylinder with a horizontal side tube for suction, was commonly used from 1913 before using citrate. The practice of blood transfusion advanced with the outbreak of World War I. Pre-transfusion testing did not become normal practice before 1915 with popularisation of sodium citrate anticoagulation and collection of blood donors. Prior to this, transfusion was only possible using defibrinated blood17 and by direct donor-to-patient techniques. In 1939 and 1940, the Rhesus blood group system discovered by Karl Landsteiner, Alexander Wiener, Philip Levine, and R.E. Stetson was the most significant advance in blood grouping and transfusion18,19 and was found to be the main cause of transfusion reactions up to that time20. Development of blood banking The main events in the development of blood banking are summarised in Table I. In the 1910s, it was discovered that by adding anticoagulant and refrigerating blood it was possible to store the blood for several days21,22. Following the work of Francis Peyton Rous and Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14


207

Cannas G, Thomas X

study showed that patients received a median of 18 units (range, 3-44) of red blood cell concentrates53. It is common practice to administer red blood cells based on a threshold haemoglobin value of 7-9 g/dL, depending on the patient's ability to tolerate anaemia. Studies have evaluated restrictive54 and augmented55 red blood cell transfusion policies in leukaemia. Although the restrictive policy was well tolerated, no bleeding reduction was documented in the augmented policy. Transfusions are given at approximately weekly intervals during intensive therapy. One unit of red blood cells increases the haemoglobin level by approximately 1 g/dL.

Platelet transfusions

iz

iS rl

Platelet transfusions are indispensable for supportive care of patients with haematological diseases. Unlike red blood cells, the history of platelet transfusions has only developed over the past 40 years. The existence of platelets and their contribution to haemostasis was described in the 1870s56. At first, whole blood was used to raise the platelet count in patients with thrombocytopenia. It was in 1910 that William W. Duke first noted that platelets from whole blood reduce the bleeding time and then evoked a potential role for platelet transfusion in therapy57. In the 1950s, platelets were collected and transfused, but only for diagnostic purposes. During World War II, observations were made that plastic surfaces and silicone-coated surfaces preserved the morphology and function of platelets. In the 1960s plastic blood bags became available which enabled platelets to be separated from blood collections by centrifugation. In 1961, the role of platelet concentrates in reducing mortality from haemorrhage in cancer patients was recognised58. Before the 1970s, thrombocytopenic bleeding was the major cause of serious morbidity and mortality in patients undergoing intensive chemotherapy. Platelet transfusions became available following the vision of Isaac Djerassi in Philadelphia59,60 and of Emil J. Freireich in Bethesda61. A platelet replacement programme initiated in children with leukaemia in 1958 showed that platelets had an effect on haemorrhage and mortality62-66. It was demonstrated that platelets stored for longer than 48 hours produced very markedly decreased post-transfusion increments 67 and that platelets could be concentrated under certain conditions at an appropriate pH and transfused as platelet concentrates68. In the 1970s platelet transfusion became routine practice when Scott Murphy and Frank H. Gardner provided evidence that platelet function was best preserved when platelets were stored at room temperature with agitation, revolutionising platelet transfusion therapy69. This resulted in the introduction of prophylactic platelet transfusions for patients with

©

SI M

TI

Se

rv

for the management of leukaemia. In the 1940s, greater understanding of the mechanisms of action of certain agents required for blood production, such as folic acid, led to the development of the first anti-folate drugs, notably ametopterin38. This opened a new era for the management of acute leukaemia. Before that time, the only form of treatment had been blood transfusion39. Without any treatment, patients with acute leukaemia died within a few weeks. When such patients were supported with only transfusions and antibiotics, they died in about 3 months40,41. The first blood transfusion in a patient with leukaemia was carried out by George Callender in 1873 at St Bartholomew's Hospital in London42. Exchange blood transfusion was first attempted for the treatment of acute leukaemia in the middle of the 19th century, but the first complete blood exsanguination transfusion in a case of leukaemia was given by Jean Bernard and Marcel Bessis in 194743. The result was a temporary remission of a few months (remissions of acute leukaemia being almost unknown at that time). Work on purine and pyrimidine metabolism led to the discovery of another important agent, 6-mercaptopurine44. Further developments followed rapidly, such as the discovery that corticosteroids had some effect in controlling some types of leukaemia, the discovery of derivatives of antibiotics, notably daunorubicin, and the discovery of the vinblastine and vincristine alkaloids derived from plants. There followed an active period of clinical trials using single or multiple agents in different combinations1. The prognosis of leukaemia, particularly the childhood forms, progressively improved45. Although progress was slower in adults, genuine advances were made46-48. Intensification of therapy, enabled by prophylactic transfusion of platelets, was resulting in long-term survival. As a result of more intensive procedures, by the end of the 1970s, 20% of patients with acute myeloid leukaemia were beginning to live 3 to 5 years49. In the mid-1970s bone marrow transplantation was introduced, and further dramatic advances were made50. Blood transfusions remain an important part of haematological care. Anaemia is an invariable consequence of acute leukaemia due to a reduction of erythropoiesis caused by the infiltration by leukaemic cells in the bone marrow and the suppressive effect of cytotoxic drug therapy. In one study, it was demonstrated that, on average, a patient suffering from acute myeloid leukaemia requires 41 units of red blood cells, 6 of fresh frozen plasma, 15 of single donor platelets, and 33 of random donor platelets51. Based on these data, it could be estimated that the average blood transfusion support requires the generous gifts of about 100 blood donors per patient52. During induction and consolidation, another




iS rl

There are a number of methods used to select HLA-matched platelet products. Commonly recipient and donor are matched for HLA A and B antigens86. A grading of the quality of matches has been defined87,88. HLA A and B antigens can be organised into cross-reactive groups on the basis of which public epitopes they share. Platelets with one or two mismatches can be used as long as these antigens fall within the same cross-reactive groups 89. The antibody specificity prediction method can also identify the specificity of HLA antibody and antigennegative platelet products90. Recently, the software tool HLAMatchmaker has been used to predict HLA compatibility by identifying immunogenic epitopes represented by amino acid triplets in antibody-accessible regions of HLA molecules91,92. Despite the lack of convincing evidence93, provision of HLA-matched platelets for patients suspected or known to have alloimmune refractoriness remains a standard of care.

Granulocyte transfusions

rv

iz

Despite antibiotic therapy, severe neutropenia remains an important and severe complication of intensive chemotherapy and haematopoietic stem cell transplantation, and can be complicated by serious infections with bacteria, yeasts, or fungi. This led to the concept of granulocyte replacement by transfusion therapy. Granulocyte transfusions were first explored in 193494, but it was not until 1953 that the first promising experiments with leucocytes were reported95. In the 1960s, enthusiasm for granulocyte transfusions was fuelled by the ability to collect granulocytes from patients with chronic myeloid leukaemia and the early success in patients with severe granulocytopenia 96-101. Cell collections yielded as many as 1×1011 phagocytic cells and transfusion led to improvement in septic neutropenic patients. However, this practice was abandoned due to the unavailability of donors and concerns about transfusing malignant cells. Sufficient granulocytes could be obtained from normal donors after stimulation with corticosteroids102-104 and rapid leukapheresis105. In the mid-1990s, the advent of recombinant granulocyte-mobilising cytokines (granulocyte colony-stimulating factor [G-CSF]), which recruit large numbers of granulocytes into the blood, the use of haemapheresis instruments and starches to increase the efficiency of the separation of red cells from granulocytes have been combined to make granulocyte transfusion feasible 106-108 . Combining glucocorticoids and cytokines results in even greater efficacy. It was demonstrated that the neutrophils induced by G-CSF to circulate have a different transcriptional profile and a much longer life-span109,110.

©

SI M

TI

Se

leukaemia, and dramatically changed the causes of death among patients with this malignancy, such that haemorrhage as a major cause of death was virtually eliminated70-73. Furthermore, the practice of prophylactic platelet transfusions enabled therapy intensification. The trigger platelet count of 10×109/L has been adopted by many centres for prophylaxis in stable patients63,74, while a threshold of 20×109/L is used for patients with bleeding, fever, infection, or a rapid fall in the platelet count71-73. These recommendations do not apply to patients with acute promyelocytic leukaemia, since their bleeding risk and platelet transfusion requirements remain higher75. Additional risk factors, such as sepsis, use of drugs, or other abnormalities of haemostasis, are indications for higher thresholds71. New methods for platelet transfusion were introduced in the 1980s using cytapheresis techniques, which led to an increase in platelet transfusion therapy to support myeloproliferative therapies including intensive chemotherapy and stem cell transplantation currently used in the treatment of leukaemia. This was refined in the 1990s with methods of collecting leucocyte-reduced platelet products. Leucocytes present in allogeneic blood components have a number of untoward side effects, such as HLA immunisation, non-haemolytic febrile transfusion reactions, virus transmission and infections76,77. Currently, platelet transfusions are of low immunogenicity. Platelets have a shelf-life of up to 7 days, and even matched platelets can be routinely delivered. Further improvements can be expected from uniform "type & screen" approaches for immunised patients and cross-matching by computer78,79. Approximately 0.6×1011 platelets can be harvested from a single unit of blood. Ten times this amount can be collected from one donor using a cell separator27. Platelet refractoriness was identified in the 1960s as a major complication of chronic platelet transfusions and linked to complement-fixing isoantibodies 80. Refractoriness to platelet transfusions is most frequently due to the presence of alloantibodies in the recipient81. Alloimmunisation is defined as occurring when an adequate platelet count increment (10 to 20×109/L) is not achieved 1 hour after transfusion82. Anti-human leucocyte antigen (anti-HLA) alloimmunisation, which is associated with febrile reactions and refractoriness to random donor platelet support, is more frequent in female patients as a possible consequence of primary sensitisation during pregnancy 83. However, alloimmunisation to platelet antigens accounts for only approximately 20% of cases of refractoriness, and results from exposure to contaminating leucocytes in platelet products84. This has been confirmed by controlled trials, particularly the Trial to Reduce Alloimmunization to Platelets (TRAP)85. Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14


209

Cannas G, Thomas X

equally successful128. Furthermore, one major drawback to prophylactic granulocyte transfusion is the increased likelihood of transfusion reactions, alloimmunisation, lymphocytotoxic antibodies, and refractoriness to future transfusions129,130. Severely immunosuppressed patients are at risk of serious complications, such as Graftversus-Host disease131,132. Granulocyte transfusions should be given in specific situations, according to well-established and standardised operational procedures for both the donor and the patient133.

Apheresis

iz

iS rl

Apheresis refers to any procedure during which blood is withdrawn from the donor or patient and separated ex vivo into some or all of its components134. The first experimental procedure was performed in 1660 by Richard Lower on dogs. Plasmapheresis, corresponding to removal of plasma and return of red cells, was first performed in France in 1902 and used in artificial kidney research at Johns Hopkins University by Roundtree and Turner in 1914135. In 1960, Alan Salomon and John L. Fahey reported the first therapeutic plasmapheresis procedure. In 1964, plasmapheresis was introduced as a means of collecting plasma for fractionation. In 1972, apheresis was used to extract one cellular component, returning the rest of the blood to the donor. In the 1980s, automated on-line cell separation devices were developed136. Granulocytes, platelets, and fresh-frozen plasma were the original components collected by means of apheresis technology. Leucostasis, manifested by headache, blurred vision, dyspnoea and hypoxia, constitutes a medical emergency, and efforts should be made to lower the white blood cell count rapidly. This can be achieved by leukapheresis. Historically, leukapheresis has been used in this setting in patients with white blood cell counts >100×109/L in those with acute myeloid leukaemia and >100-200×109/L in those with acute lymphoblastic leukaemia and neurological and pulmonary symptoms suggestive of leucostasis137. However, it remains controversial as to whether reducing circulating blasts by leukapheresis results in less mortality, and improvement in asymptomatic patients138-140.

©

SI M

TI

Se

rv

Despite technical problems, toxicity, and undefined therapeutic advantage, some controlled studies have shown benefit when using granulocyte transfusions, particularly when more than 1×10 10 cells were transfused105. A meta-analysis of randomised controlled studies 111-116 concluded that there were significant survival benefits in the following settings: low survival rate of controls, adequate dose of granulocytes, timely marrow recovery, and pre-transfusion assessment of compatibility of granulocytes117. However, all the studies included in the meta-analysis had been conducted prior to the availability of new-generation antibiotics and antifungal drugs. Granulocyte therapy was not efficacious when buffy coats containing less than 0.5×109/kg granulocytes were transfused. Apheresis procedures are performed with a special centrifuge118. The leucocyte-containing layer is harvested to form the granulocyte concentrate, and red cells and plasma are returned to the donor. The ability of granulocytes to adhere to nylon in the presence of divalent cations was also initially exploited to separate the cells, but was later abandoned119. The addition of a rouleauxinducing sedimenting agent enhances the separation of red cells from white cells and increases yields as much as two-fold. The most common rouleaux-inducing agents employed are hydroxyethyl starches99-101. The benefit of granulocyte transfusions also depends on compatibility with any alloantibodies present and matching might have a role in selected conditions120. The indications for granulocyte transfusion are not well defined. Patients may benefit from granulocyte transfusions when serious infection is present and if neutropenia is expected to last for more than several days. When possible, attempts should be made to match for leucocyte antigens and transfuse cytomegalovirusnegative, irradiated cells. Despite more than 15 years of experience with G-CSF-stimulated granulocyte transfusions, it is still unclear whether this therapy really affects the resolution of infection and reduces mortality121,122. Only one randomised phase III study of therapeutic granulocyte transfusions in neutropenic patients has been reported123. However, the data presented were of no use for rejecting or proving the clinical value of granulocyte transfusions. Prophylactic granulocyte transfusions did not improve the outcome of patients124,125. There were only reductions in the percentage of patients with fever, median number of febrile days, days on antibiotics and the percentage of patients with bacteraemia126. Granulocyte transfusions have also been used as secondary prophylaxis against fungal infections. In a study of patients given granulocyte transfusions, none of the patients included had reactivation of their previous infections127, but voriconazole alone was

Stem cell harvesting

Recently, novel apheresis procedures have been developed for the collection of different combinations of blood components from healthy donors141. Details on the methods of preparation and content of blood components can be found in the North American "Technical Manual" of the American Association of Blood Banks (AABB)142 and in the European "Guide to the preparation, use and quality assurance of blood components"143. Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14

210



rv

iz

iS rl

blood stem cell transplantation results in rapid, multilineage engraftment following successful mobilisation of donor stem cells with G-CSF163-165. Nevertheless, early enthusiasm was offset by reports of chronic Graft-versus-Host disease, which occurred despite the low numbers of CD3+ cells present in the blood stem-cell suspension following CD34+ cell selection166. Diminishing the Graft-versus-Host effect while retaining the graft-versus-leukaemia effect remains a challenge167. Results of the first successful trials were published in 1995168-170. Allogeneic blood cell collection and reinfusion (donor lymphocyte infusion) may be of benefit to bone marrow transplant patients with recurrent leukaemia. This form of immunotherapy uses the inherent immune reactivity of apheresis-derived allogeneic leucocytes from the original donor either to prevent recurrence or to re-induce remission. With strategies that manipulate the timing and the dose of T lymphocytes infused following transplantation, this therapy attempts to exploit the beneficial graft-versusleukaemia effect while minimising the risks of Graftversus-Host disease167,171. More recently, the role of photopheresis in managing Graft-versus-Host disease after haematopoietic stem cell transplantation has been developed172. Cord blood transplantation, an extension of peripheral blood stem cell harvesting from a neonate's cord blood, was first introduced in 1989173. It has now become a widely used stem-cell transplantation option in children and in adults174.

Se

Peripheral blood stem cell harvests Peripheral blood stem cell transplantation was introduced in 1986 as a transplant modality, and has now replaced bone marrow as the source of stem cells in almost 100% of autologous transplants and approximately 75% of allogeneic transplants144. Since the hypothesis in 1909 that haematopoietic stem cells circulate145 and subsequently the discovery of dividing non-leukaemic DNA-synthesising cells in peripheral blood146, the demonstration that stem cells from shielded haematopoietic tissue areas entered the circulating blood and subsequently repopulated the irradiated bone marrow147, the demonstration of haematopoietic reconstitution following myeloablative irradiation and parabiosis in rodents148 and cross-circulation experiments in large animals149, the applications of haematopoietic stem cells in humans have emerged. The next step was to harvest circulating white blood cells and, among them, putative stem cells. "Blood stem cells" were then introduced as a transplantable cell population in the early 1960s150. The first attempts at haematopoietic stem-cell transplantation into lethally irradiated large animals were not pursued at a clinical level because of the rarity of circulating stem cells at steady state151,152. Improvements came from the development of the continuous-flow apheresis technology in the 1960s and the early 1970s153,154.

©

SI M

TI

Peripheral blood autologous stem cell harvests The modern era of autologous blood stem cell transplantation began in the 1980s with the documentation that, using multiple leukaphereses, there were sufficient numbers of autologous hematopoietic stem cells in steady-state blood to ensure engraftment after myeloablative therapy155. The autologous transplant modality also benefited from improvements regarding cryopreservation technologies156. The first successful autologous stem cell transplant in a patient with chronic myeloid leukaemia was performed in 1979157, after cell engraftment was demonstrated in a patient receiving granulocytes derived from a donor with chronic myeloid leukaemia158. The first successful hematopoietic reconstitution after autologous blood stem cell transplantation was described in 1986159. Initially autologous stem cells were used to shorten the period of pancytopenia following myeloablative chemotherapy160. Peripheral blood allogeneic stem cell harvests The first mobilisation study on healthy donors was published in Japan in 1993161. The first attempt to transplant non-mobilised T-cell-depleted peripheral blood stem cells into a HLA-identical sibling was performed in 1989162. G-CSF-mobilised stem cells were used in this setting 4 years later163. Allogeneic

Non-mobilised stem cell harvests Circulating haematopoietic stem cells have been harvested in steady-state by apheresis without specific mobilisation strategies. Engraftment times are comparable to those obtained after transplantation of bone marrow155,159,175. However, apheresis-derived blood stem cells offer several benefits over marrow transplants168. The disadvantages include a longer time to obtain an adequate harvest, a greater volume to infuse, and, in the allogeneic setting, the possibly greater risk of Graft-versus-Host disease176.

Mobilised stem cell harvests Mobilisation strategies have significantly improved the efficiency of peripheral blood stem cell collection by apheresis and have decreased the number of procedures necessary to collect target amounts of stem cells. Stem cells can be harvested during the recovery phase following myelosuppressive chemotherapy, a period associated with increased concentrations of circulating haematopoietic progenitor cells177,178. Since their first descriptions in 1988179,180, mobilisation regimens have incorporated cytokines, such as G-CSF or granulocytemacrophage colony-stimulating factor (GM-CSF)181,182,

Blood Transfus 2015; 13: 205-20 DOI 10.2450/2014.0080-14 All rights reserved - For personal use only No other use without premission

211

Cannas G, Thomas X

iS rl

iz

Viruses In 1943, Paul Beeson (1908-2006) linked the occurrence of jaundice in seven cases to blood or plasma transfusions, providing the quintessential description of transfusion-transmitted hepatitis. During the Korean War, 22% of those who were transfused developed hepatitis200. "Serum hepatitis" transmitted by whole blood or plasma was presumed of viral origin. In 1965, Baruch Blumberg of the National Institutes of Health discovered Australia antigen (HbsAg) in aborigines and showed the presence of the antigen at high frequency in patients with leukaemia and children with Down's syndrome201. In 1971, Blumberg identified a substance on the surface of the hepatitis B virus that triggers the production of antibodies. This led to the development of a test identifying infected donors202. In the 1980s, investigators from the Centers for Disease Control203 and Chiron (Emeryville, California)204 identified the virus of hepatitis C. In 1990, blood banks began screening blood donors for hepatitis C, but it was not until 1992 that a blood test was perfected that effectively eliminated the virus from the blood transfusion supply. In 1981, the first cases of acquired immune deficiency syndrome (AIDS), a syndrome initially called gay-related immunodeficiency disease (GRID), were reported. In 1982, Bruce Evatt suspected that AIDS was blood-borne after the discovery of the disease among haemophiliacs. The virus that causes AIDS was isolated as LAV (lymphadenopathy-associated virus) in 1983 by Luc Montagnier at the Pasteur Institute in Paris (who was awarded the Nobel Prize in Physiology or Medicine in 2008)205, while Robert Gallo from the National Institutes

Se

Infections transmitted by transfusion

into each bottle of preserved blood, converting 99% of the haemoglobin to oxyhaemoglobin. The earliest efforts to prevent a transmission-transmitted infection involved syphilis. The first identified cases of transmission of syphilis by direct transfusion were published after 1915195. However, spirochaetes do not survive well in citrated blood stored for more than 72 hours. In 1947, syphilis testing was performed on each unit of blood. While bacterial contamination in re-used glass bottles was among the earliest causes of transfusionrelated infections196, the introduction of sterile plastic container systems and controlled refrigeration of blood components almost completely eliminated this problem by the 1960s197. However, technical developments, including sterile docking devices, allowed prolonged storage of platelets at room temperature and bacterial contamination of platelets remained a significant issue complicating transfusions198,199. Improved donor selection and special screening techniques have minimised the risk of this complication during the last decade.

rv

in addition to chemotherapy, in order to increase progenitor cell concentrations over steady-state blood levels. Repeated daily collections over 2 to 5 days were used to reach an adequate threshold of stem cells. Follow-up studies showed a mobilisation advantage of G-CSF over GM-CSF183. More recently, plerixafor, a small molecule antagonist which reversibly inhibits the interaction of the chemokine stromal cell-derived factor 1 with its cognate receptor, CXCR4, was used for stem-cell mobilisation184. The first clinical study with plerixafor used for the mobilisation of haematopoietic progenitor cells in healthy donors was published in 2003185, after studying the drug's pharmacokinetics in healthy volunteers186. The combination of G-CSF and plerixafor has become the standard treatment regimen in difficult-to-mobilise patients after finding that the combination has a synergistic effect on the mobilisation of CD34+ cells 187. The number of circulating CD34+ cells on the day of leukapheresis is an accurate predictor of the optimal time of stem cell harvest188,189. The adequacy of the collection is dependent on the mode of mobilisation, the timing of the collection with respect to the recovering leucocytes, the volume of whole blood processed, and the amount of pre-treatment the patient has received190.

©

SI M

TI

Because patients with leukaemia develop infections very easily, they systematically receive antibiotics and other drugs to protect them from infections. All types of infections can occur; they may be present at diagnosis or arise during the treatment of the leukaemia and subsequent follow-up and can be caused by micro-organisms normally present in the environment or the host which become more pathogenic by reason of changes in the patient's defences. Transmission of infections by transfusion has also occurred. However, current preventive screening methods are becoming increasingly effective191. Reliance on single-donor rather than pooled whole blood-derived platelets was proposed to reduce the risk of transfusion-associated sepsis192,193. Bacteria Historically, there was concern about transmitting infectious diseases from a donor to a recipient. With regards to safe transfusions, the dangers of infection (both local and systemic) started to be resolved when, in 1865, Louis Pasteur (1822-1895) recognised that bacterial or fungal contamination causes putrefaction, and Joseph Lister (1827-1912), an English surgeon, used antiseptics in 1867 to control infection during blood transfusions. As a result, the sterilisation of instruments and antiseptic methods began to be introduced194. During the Spanish Civil War, in an attempt to prevent the growth of anaerobic bacteria, pressurised air was forced




encephalopathy-affected countries, particularly Great Britain, during the years of likely exposure. Universal white blood cell reduction was introduced in Europe in an attempt to prevent transmission of variant Creutzfeldt-Jakob disease by transfusion215.

Other risks of transfusion

rv

iz

iS rl

Transfusion-related risks other than infectious diseases should be taken into account, such as post-transfusion reactions. These reactions include transfusion-related lung injury (TRALI) during which the donor's immune antibodies cause breathing problems in the recipient216. This condition was first described in 1957217, but its specific clinical and radiographic findings were defined in the 1980s218. TRALI can be due to white blood cell antibodies, soluble biological response mediators accumulating during the storage of cellular blood components, or other still unidentified agents contained in blood components 216,219. Other reactions include transfusion-associated cardiac overload (TACO), and post-transfusion iron overload which is a build-up of iron in the body usually caused by multiple or regular transfusions220. Alloimmunisation occurs when the recipient develops a reaction to the donor's red blood cells. This includes transfusion-related immune modulation (TRIM). TRIM effects may be mediated by allogeneic mononuclear cells, white blood cell-derived soluble mediators, and/or soluble HLA peptides circulating in allogeneic plasma221-223. Another complication attributable to leucocytes is a febrile reaction. Passage of blood through a filter containing nylon fibres was introduced in 1962 to prevent such reactions224. Modifying the blood before transfusion can also reduce these reactions. Using male plasma and platelets may eliminate the transmission of certain antibodies, which can be found in previously pregnant women and transfused males. Alternatively, new technologies can be used to collect large amounts of red blood cells and platelets from a single donor, decreasing the number of donors to whom a transfused patient is exposed225. Reduction of inappropriate transfusions is another, and perhaps better, approach to reducing donor exposure.

©

SI M

TI

Se

of Health announced its identification in 1984 as HTLVIII (human T-cell lymphotropic virus)206. A legal battle ensued over who should be credited for the discovery, which ended in 1987 when the United States and French governments agreed to share credit and royalties from the sales of test kits for the virus. The first screening test (an enzyme-linked immunosorbent assay) was licensed in 1985207. The human immunodeficiency virus (HIV) epidemic during the 1980s was a major cause of fear, after the suspicion that AIDS could be transmitted by means of transfusion was confirmed208,209. The blood bank community has been chastised for its perceived failure to act during the early years of the AIDS epidemic, and many lawsuits were brought for being late to introduce a surrogate marker for HIV and to introduce inactivation measures for clotting factor concentrates210. One positive outcome of that outbreak tragedy was a new paradigm in blood transfusion, the precautionary principle 211, which prompted the development of haemovigilance, tracing and tracking transfusion-related adverse events and incidents affecting blood donors and recipients. Since then a series of more sensitive tests have been developed and implemented to screen donated blood for viral diseases: two tests that screen for indirect evidence of hepatitis, i.e. detection of antibodies to hepatitis B core antigen (anti-HBc) and assays of alanine aminotransferase levels (1987); the human T-lymphotropic-virus-I-antibody (anti-HTLV-I) test (1989); the hepatitis C virus test (1990); the HIV-1 and HIV-2 antibodies test (1992), the HIV p24 antigen test (1996); and nucleic acid amplification testing, which directly detects the genetic material of viruses such as HCV and HIV (1999). These developments have greatly increased the safety of blood transfusion. New methods, including novel molecular and micro-array testing, which can identify many infectious agents, will be developed in the near future. Prions Creutzfeld-Jacob disease is not known to have been transmitted by transfusion. In 1996, variant CreutzfeldJacob disease, caused by the same strain of prion as bovine spongiform encephalopathy, was identified. The first possible transmission of variant Creutzfeld-Jacob disease by blood transfusion was reported in 1998212. Since then, transfusion-transmitted cases have been traced to donors who became symptomatic with variant Creutzfeld-Jacob disease 3 or more years after the index donation213,214. Because of the long, asymptomatic carrier state and the strong resistance of prions to inactivation procedures, the primary intervention to prevent transfusion-transmitted cases of variant CreutzfeldJacob at present is to defer indefinitely any potential who have a history of visiting bovine spongiform

Conclusion

Transfusion medicine already has a long history and it is continuing to advance into new areas which could potentially have an impact on the treatment of acute leukaemia. The clinical promise of cellular therapies is strengthening rapidly. The field of hematopoietic stem cell transplantation is shifting from cell replacement therapy to adoptive cellular therapy. Lymphocytes collected from haematopoietic stem cell donors have been infused as an adoptive cellular therapy to treat leukaemia


213

Cannas G, Thomas X

Recently, gas-permeable flasks have been used to expand cytotoxic T cells to a much higher concentration than possible with bags or traditional flasks239. The progress in adoptive cellular therapy in leukaemia parallels the rapid evolution of immunology, gene therapy and stem cell biology, and the translation of advances in these fields from research to the clinic. Keywords: history, leukaemia, transfusion, supportive care. The Authors declare no conflict of interest.

References

iz

iS rl

1) George P, Hernandez K, Hustu O, et al. A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr 1968; 72: 399-408. 2) British Medical Journal. Transfusion of blood in leukaemia [Editorial]. Br Med J 1873; 1: 593. 3) Landsteiner K. Uber agglutinationserscheinungen normalen mensclinchen blutes. Wiener Klin Wochen 1901; 1: 5-8 [In German]. 4) Boyle R. Some Considerations Touching the Usefulness of Experimental Natural Philosophy. Oxford; 1663. p. 63-5. 5) Lower R. The method observed in transfusing blood out of one live animal into another. PhilosTrans R Soc Lond 1666; 1: 353-8. 6) Denis JB. Lettre écrite à Monsieur Montmort, touchant une nouvelle manière de guérir plusieurs maladies par la transfusion du sang. Paris: Jean Cusson; 25 June 1667 [In French]. 7) Decastello A, Sturli A. Ueber die isoagglutinine im serum gesunder und kranker menschen. Munch Med Wschr 1902; 49: 1090-5 [In German]. 8) Jansky J. Haematologicke, studie u psychotiku. Sb Klin Praze 1907; 8: 85-139 [In Czech]. 9) Moss WL. Studies on isoagglutinins and isohemolysins. Bull Johns Hopkins Hospital 1910; 21: 63-70. 10) Landsteiner K, Levine P. A new agglutinable factor differentiating individual human bloods. Proc Soc Exp Biol NY 1927; 24: 600-2. 11) Sanger R, Race RR. Subdivisions of the MN blood groups in man. Nature 1947; 160: 505. 12) Landsteiner K, Levine P. Further observations on individual differences of human blood. Proc Soc Exp Biol NY 1927; 24: 941-2. 13) Ottenburg R, Kaliski DJ. Accidents in transfusion; their prevention by preliminary blood examination based on an experience of one hundred and twenty-eight transfusions. JAMA 1913; 61: 2138-40. 14) Epstein AA, Ottenburg R. A simple method of performing serum reactions. Proc NY Pathol Soc 1908; 8: 117-23. 15) Ottenburg R. Studies in isoagglutination. I: Transfusion and the question of intravascular agglutination. J Exp Med 1911; 13: 425-38. 16) Walker LG Jr. Carrel's direct transfusion of a five day old infant. Surg Gynecol Obstet 1973; 137: 494-6. 17) Moss WL. A simple method for the indirect transfusion of blood. Am J Med Sci 1914; 147: 698-703. 18) Levine P, Stetson RE. An unusual case of intragroup agglutination. JAMA 1939; 113: 126-7. 19) Landsteiner K, Wiener AS. An agglutinate factor in human blood recognised by immune sera for Rhesus blood. Proc Soc Exp Biol NY 1940; 43: 223. 20) Wiener AS, Peters HR. Haemolytic reactions following transfusions of blood of the homologous group, with three

©

SI M

TI

Se

rv

relapses following allogeneic transplantation171. New techniques can isolate specific cell populations from blood. Most importantly, haematopoietic progenitor cells can be isolated and used for haematopoietic stem cell transplantation. In the future, these cells may be grown and expanded for clinical use. Similarly, specialised cell types may be isolated and used in cellular therapy because of their action on proliferation and immune responses during the engraftment of transplanted cells. Epstein-Barr virus-specific cytotoxic T cells, generated in vitro, can mediate antiviral and even antitumour effects in vivo226-228. Cytotoxic lymphocytes of other specificities are also under evaluation. T cells specific to leukaemia antigens such as Wilms' tumour 1 (WT1)229,230 and proteinase 3 (PR3)231 are under investigation to prevent or treat leukaemia relapse following allogeneic stem cell transplantation. Recently, vaccination has been able to induce T-cell responses against cancer-associated antigens. This offers the prospect of combining vaccine strategies with adoptive transfer of specific T cells to achieve optimal T-cell expansion and therapeutic benefit232. Adoptive cellular therapy protocols have also begun to use natural killer (NK) cells. NK cells from the stem cell transplant donors are being administering post-transplantation233. The allogeneic NK cells are administered to the recipient at the time of disease relapse. The recipient is immunosuppressed and treated with interleukin-2 to allow in vivo NK cell expansion. This NK cell therapy has resulted in complete haematological remission in patients with acute myeloid leukaemia234. Dendritic cells generated by incubating peripheral blood monocytes with the differentiating agents interleukin-4 and GM-CSF to produce immature dendritic cells have been used in clinical trials, but for most trials they have been incubated with maturation agents to produce mature dendritic cells235. However, many trials are now using genetically engineered dendritic cells to epitope-load HLA antigens230. Another promising use of genetically engineered cells involves arming autologous T cells with T-cell receptors that have a high affinity for cancer antigens, expanding these genetically modified T cells in vitro and infusing them into patients236. Chimeric antigen T-cell receptors (CAR) are also being used in adoptive cell therapy. One CAR that has been tested clinically is made up of the antigen recognition portion of CD19, the zeta chain of the T-cell receptor and a portion of the co-stimulatory molecule CD28. Autologous T cells transduced with anti-CD19 CAR are cytolytic to malignant B cells that express CD19237. Although clinical trials of these genetically engineered T cells are just beginning, preliminary results have been encouraging238. Investigators are working on cell-reprogramming strategies to produce naïve and stem T cells for adoptive cellular therapy.




rv

iz

iS rl

46) Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-23. 47) Boiron M, Weil M, Jacquillat C, et al. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet 1969; 1: 330-3. 48) Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973; 41: 489-96. 49) Freireich EJ. Four decades of therapy for AML. Leukemia 1998; 12: S54-6. 50) Thomas ED, Fefer A, Buckner CD, Storb R. Current status of bone marrow transplantation for aplastic anaemia and acute leukemia. Blood 1977; 49: 671-81. 51) Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999; 39: 925-32. 52) Rebulla P. Transfusion support and hematopoietic growth factors. In: Faderl S, Kantarjian H, editors. Leukemias: Principles and Practice of Therapy. 1st ed. Oxford: WileyBlackwell; 2010. 53) Favre G, Fopp M, Gmur J, et al. Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol 1993; 67: 153-60. 54) Jansen AJ, Caljouw MA, Hop WC, et al. Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukemia. Transfus Med 2004; 14: 33-8. 55) Webert KE, Cook RJ, Couban S, et al. A multicenter pilotrandomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008; 48: 81-91. 56) Bizzozero G. Ueber einen neuen formbestandtheil des blutes und dessen rolle bei der thrombose und der blutgerinnung. Virchow Arch Pathol Anat Physiol 1882; 90: 261-332 [In German]. 57) Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by blood transfusion. JAMA 1910; 55: 1185-92. 58) Heyman MR, Schiffer CA. Platelet transfusion for the cancer patient. Semin Oncol 1990; 17: 198-209. 59) Djerassi I, Farber S. Conference on obstacles to the control of acute leukemia. Control and prevention of hemorrhage: platelet transfusion. Cancer Res 1965; 25: 1499-503. 60) Djerassi I. Platelet transfusions and supportive care. A requirement for currently effective chemotherapy. JAMA 1972; 222: 1172-3. 61) Freireich EJ. Origins of platelet transfusion therapy. Transfusion Med Rev 2011; 25: 252-6. 62) Freireich EJ, Schmidt PJ, Schneiderman MA, et al. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N Engl J Med 1959; 260: 6-11. 63) Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905-9. 64) Kliman A, Gaydos LA, Schroeder LR, et al. Repeated plasmapheresis of blood donors as a source of platelets. Blood 1961; 18: 303-9. 65) Kliman A, Carbone PP, Gaydos LA, et al. Effects of intensive plasmapheresis on normal blood donors. Blood 1964; 23: 647-56. 66) Freireich EJ, Kliman A, Gaydos LA, et al. Response to repeated platelet transfusions from the same donor. Ann Intern Med 1963; 59: 277-87. 67) Levin RH, Freireich EJ. Effect of storage up to 48 hours on response to transfusions of platelet rich plasma. Transfusion 1964; 4: 251-6.

©

SI M

TI

Se

cases in which the same agglutinogen was responsible. Ann Int Med 1940; 13: 2306-22. 21) Rous P, Turner TR. The preservation of living red blood cells in vitro. J Exp Med 1916; 23: 219-48. 22) Weil R. Sodium citrate in the transfusion of blood. JAMA 1915; 64: 425-6. 23) Robertson OH. Transfusion with preserved red blood cells. BMJ 1918; 1: 691-5. 24) Oliver PL. A plea for a national blood transfusion conference. Br Med J 1936; 2: 1032-3. 25) Yudin SS. Transfusion of cadaver blood. JAMA 1936; 106: 997-9. 26) Fantus B. The therapy of the Cook County Hospital. JAMA 1937; 109: 128-131. 27) Mollison PL, Engelfriet CP, Contreras M. Blood Transfusion in Clinical Medicine. 10th ed. Oxford: Blackwell Science; 1997. 28) Diamond LK. History of blood banking in the United States. JAMA 1965; 193: 40-5. 29) Love S. The Death and Resurrection of Charles R. Drew. Chapel Hill: University of North Carolina Press; 1996. 30) Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions in human plasma. J Clin Invest 1944; 23: 417-32. 31) Cohn EJ. The separation of blood into fractions of therapeutic value. Ann Intern Med 1947; 26: 341-52. 32) Loutit JF, Mollison PL. Advantages of a disodium-citrate-glucose mixture as a blood preservative. Br Med J 1943; 2: 744-5. 33) Högman C, Erikkson L, Gong J, et al. Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use. Vox Sang 1993; 65: 271-8. 34) Sturgeon P, Cedergren B, McQuiston D. Automation of routine blood typing procedures. Vox Sang 1963; 20: 438-51. 35) Allen FH Jr, Rosenfield RE, Adebahr MR. Kidd and Duffy blood typing without Coombs serum. Adaptation of the analyzer hemagglutination system. Vox Sang 1963; 76: 698-706. 36) Marsch WL, Nichols M, Jenkins WJ. Automated detection of blood group antibodies. J Med Lab Technol 1968; 25: 335-42. 37) Christie DA, Tansey EM. Leukaemia. Wellcome Witnesses to Twentieth Century Medicine. vol. 15. London: The Wellcome Trust Centre for the History of Medicine at UCL; 2003. p. 86. 38) Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-amethopteroylglutamic acid (ametopterin). N Engl J Med 1948; 238: 787-93. 39) Hayhoe FGJ, Whitby L. The management of acute leukaemia in adults. Br J Haematol 1955; 1: 1-19. 40) Wadham Dr. A mirror of hospital practice, British and foreign. St George's Hospital. Case of leucocythaemia in a child aged five years and a half; necropsy; remarks. Lancet 1884; 123: 158-9. 41) Tivey H. The natural history of untreated acute leukemia. Ann NY Acad Sci 1954; 60: 322-58. 42) Piller GJ. Historical review. Leukaemia – a brief historical review from ancient times to 1950. Br J Haematol 2001; 112: 282-92. 43) Bessis M, Bernard J. Remarquables résultats du traitement d'un cas de leucémie aiguë par l'exsanguino-transfusion. Bull Mémoires Soc Méd Hôp Paris 1947; 63: 871 [In French]. 44) Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new anti-metabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953; 8: 965-99. 45) Pinkel D, Simone J, Hustu HO, Aut RJ. Nine years' experience with "Total Therapy" of childhood acute lymphocytic leukemia. Pediatrics 1972; 50: 246-51.


215

Cannas G, Thomas X

iz

iS rl

the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 1977; 50: 407-12. 89) Vassallo RR. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007; 14: 655-63. 90) Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-56. 91) Nambiar A, Duquesnoy RJ, Adams S, et al. HLAMatchmakerdriven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107: 1680-7. 92) Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77: 525-34. 93) Pavenski K, Rebulla P, Duquesnoy R, et al. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013; 53: 2230-42. 94) Strumia MM. Effect of leukocyte cream injection in the treatment of the neutropenias. Am J Med Sci 1934; 187: 527-44. 95) Brecher G, Wilbur KM, Cronkite EP. Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Proc Soc Exp Biol Med 1953; 84: 54-6. 96) Freireich EJ, Levin RH, Whang J, et al. The function and the fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic patients. Ann NY Acad Sci 1964; 113: 1081-9. 97) Eyre HJ, Goldstein IM, Perry S, Graw RG Jr. Leukocyte transfusions: function of transfused granulocytes from donors with chronic myelocytic leukemia. Blood 1970; 36: 432-42. 98) Debelak KM, Epstein RB, Andersen RB. Granulocyte transfusion in leukopenic dogs: in vivo and in vitro function of granulocytes obtained by continuous-flow filtration leukopheresis. Blood 1974; 43: 757-66. 99) McCredie KB, Freireich EJ, Hester JP, Vallejos C. Increased granulocyte collection with the blood cell separator and the addition of etiocholanolone and hydroxyethyl starch. Transfusion 1974; 14: 357-64. 100) Schiffer CA, Aisner J, Dutcher JP, Wiernik PH. Sustained post-transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J Hematol 1983; 15: 65-74. 101) Mishler JM, Hadlock DE, Fortuny IE, et al. Increased efficiency of leukocyte separation by the addition of hydroxyethyl starch to the continuous flow centrifuge. Blood 1974; 44: 571-81. 102) Mishler JM. The effects of corticosteroids on mobilization and function of neutrophils. Exp Hematol 1977; 5 (Suppl): 15-31. 103) Higby DJ, Mishler JM, Rhomberg W, et al. The effect of a single or double dose of dexamethasone on granulocyte collection with a continuous flow centrifuge. Vox Sang 1975; 28: 243-8. 104) Winton EF, Vogler WR. Development of a practical oral dexamethasone premedication schedule leading to improved granulocyte yields with the continuous-flow centrifugal blood cell separator. Blood 1978; 52: 249-53. 105) Strauss RG. Neutrophil (granulocyte) transfusions in the millennium. Transfusion 1998; 38: 710-2. 106) Caspar CB, Segar RA, Burger J, Gmür J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-71. 107) Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-8. 108) Jendiroba DB, Lichtiger B, Anaissie E, et al. Evaluation and

©

SI M

TI

Se

rv

68) Levin RH, Pert JH, Freireich EJ. Response to transfusion of platelets pooled from multiple donors and the effects of various techniques of concentrating platelets. Transfusion 1965; 5: 54-63. 69) Murphy S, Gardner FH. Platelet storage at 22°C; metabolic, morphologic, and functional studies. J Clin Invest 1971; 50: 370-7. 70) Hersh EM, Bodey GP, Nies BA, et al. Causes of death in acute leukemia. A ten year study of 414 patients. JAMA 1965; 193: 105-9. 71) Menitove JE, Snyder EL. Platelet transfusion practice: time for renewed consensus. Transfusion 1998; 38: 707-9. 72) Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870-5. 73) Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38. 74) Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol 1997; 15: 1143-50. 75) Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-53. 76) Bordin JO, Fabron A Jr. Clinical applications of leukocyte filters. Rev Assoc Med Bras 1997; 43: 205-8. 77) Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84: 1703-21. 78) Brand A, Novotny V, Tomson B. Platelet transfusion therapy: from 1973 to 2005. Human Immunol 2006; 67: 413-8. 79) Friedberg RC, Donnelly SF, Mintz PD. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994; 34: 215-20. 80) Aster RH, Levin RH, Cooper H, Freireich EJ. Complementfixing platelet iso-antibodies in serum of transfused persons. Correlation of antibodies with platelet survival in thrombocytopenic patients. Transfusion 1964; 4: 428-40. 81) Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunised haematologic-oncologic patients. Transfus Med 1996; 6: 111-4. 82) Daly PA, Schiffer CA, Aisner J, et al. Platelet transfusion therapy: one-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243: 435-8. 83) Slichter SJ, Davis K, Enright H, et al. factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14. 84) Claas FH, Smeenk RJ, Schmidt R, et al. Alloimmunization against MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981; 9: 84-9. 85) The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-9. 86) Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion therapy - the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969; 281: 1208-12. 87) Tosato G, Appelbaum FR, Deisseroth AB. HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 1978; 52: 846-54. 88) Duquesnoy RJ, Filip DJ, Aster RH. Influence of HLA-A2 on




rv

iz

iS rl

128) Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8. 129) Schiffer CA, Aisner J, Daily PA, et al. Alloimmunization following prophylactic granulocyte transfusion. Blood 1979; 54: 766-74. 130) Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion 2009; 49: 513-8. 131) Ford JM, Lucey JJ, Cullen MH, et al. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet 1976; 2: 1167-9. 132) Van de Wetering MD, Weggelaar N, Offringa M, et al. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. Eur J Cancer 2007; 43: 2082-92. 133) Drewniak A, Kuijpers TW. Granulocyte transfusion therapy: randomization after all? Haematologica 2009; 94: 1644-8. 134) Gilcher RO, Smith JW. Apheresis: principles and technology of hemapheresis. In: Simon TL, Snyder EL, Solheim BG, et al., editors. Rossi's Principles of Transfusion Medicine. 4th ed. Blackwell Publishing; 2009. p. 617-27. 135) Huestis DW, Bove JR, Busch S. Practical Blood Transfusion. 3rd ed. Boston: Little, Brown and Company; 1981. p. 315-72. 136) Millward PA, Bandarenko N, Brecher ME. Therapeutic apheresis: basic principles and practical aspects. In: Hillyer CD, editor. Blood Banking and Transfusion Medicine. 2nd ed. London: Churchill Livingstone; 2006. p. 727-737. 137) Strauss RA, Gloster ES, McCallister JA, et al. Acute cytoreduction techniques in early treatment of hyperleukocytosis associated with childhood hematologic malignancies. Med Pediatr Oncol 1985; 13: 346-51. 138) Maurer HS, Steinherz PG, Gaynon PS, et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol 1988; 6: 1425-32. 139) Bunin NJ, Kunkel K, Callihan TR. Cytoreductive procedures in the early management in cases of leukemia and hyperleukocytosis in children. Med Pediatr Oncol 1987; 15: 232-5. 140) Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007; 33: 350-4. 141) Popovsky MA. Multicomponent apheresis blood collection in the United States: current status and future directions. Transfus Apher Sci 2005; 32: 299-304. 142) Brecker ME. AABB Technical Manual. 15th ed. Bethesda: American Association of Blood Banks; 2005. 143) The European Directorate for the Quality of Medicines. Guide to the Preparation, Use and Quality Assurance of Blood Components. 13th ed. Strasbourg: Council of Europe Publishing; 2007. 144) Körbling M, Freireich EJ. Twenty-five years of peripheral blood stem cell transplantation. Blood 2011; 117: 6411-6. 145) Maximow A. Der Lymphozyt als gemeinsame Stamzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere. Folia Haematol 1909; 8: 125-34 [In German]. 146) Bond VP, Cronkite EP, Fliedner TM, Schork P. Deoxyribonucleic acid synthesizing cells in peripheral blood of normal human beings. Science 1958; 128: 202-3. 147) Swift MN, Taketa ST, Bond VP. Efficacy of hematopoietic protective procedure in rats x-irradiated with intestine shielded. Radiat Res 1956; 4: 186-92. 148) Brecher G, Cronkite EP. Post-irradiation parabiosis and survival in rats. Proc Soc Exp Biol Med 1951; 77: 292-4. 149) Storb R, Graham TC, Epstein RB, et al. Demonstration of

©

SI M

TI

Se

comparison of three mobilization methods for the collection of granulocytes. Transfusion 1998; 38: 722-8. 109) De Haas M, Kerst JM, van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885-94. 110) Drewniak A, van Raam BJ, Geissler J, et al. Changes in gene expression of granulocytes during in vivo G-CSF/ dexamethasone mobilization for transfusion purposes. Blood 2009; 114: 5979-98. 111) Higby DJ, Yates JW, Henderson ES, Holland JF. Filtration leukapheresis for granulocytic transfusion therapy. N Engl J Med 1975; 292: 761-6. 112) Fortuny IE, Bloomfield CD, Hadlock DE, et al. Granulocyte transfusion. A controlled study in patients with acute nonlymphocytic leukemia. Transfusion 1975; 15: 548-58. 113) Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977; 63: 548-55. 114) Herzig RH, Herzig GP, Graw RG Jr, et al. Successful granulocyte transfusion therapy for gram-negative septicaemia. A prospectively randomized controlled study. N Engl J Med 1977; 296: 701-5. 115) Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977; 296: 706-11. 116) Winston DJ, Ho WG, Gale RP. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 1980; 68: 893-7. 117) Vamvakas EC, Pineda A. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 1996; 11: 1-9. 118) MacPherson JL, Nusbacher J, Bennett JM. The acquisition of granulocytes by leukapheresis: a comparison of continuous flow centrifugation and filtration leukapheresis in normal and corticosteroid-stimulated donors. Transfusion 1976; 16: 221-8. 119) Djerassi I, Kim JS, Suvansri U, et al. Continuous-flow filtration leukapheresis. Transfusion 1972; 12: 75-83. 120) Dale DC. Renewed interest in granulocytic transfusion therapy. Br J Haematol 1997; 98: 497. 121) Peters C. Granulocyte transfusions in neutropenic patients: beneficial effects proven? Vox Sang 2009; 96: 275-83. 122) Safdar A, Hanna HA, Boktour M, et al. Impact of highdose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-65. 123) Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008; 42: 679-84. 124) Clift RA, Sanders JE, Thomas ED, et al. Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplants. N Engl J Med 1978; 298: 1052-7. 125) Strauss RG, Connett JE, Gale RP, et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 1981; 305: 597-603. 126) Oza A, Hallemeier C, Goodnough L, et al. Granulocytecolony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 2006; 46: 14-23. 127) Kerr JP, Liakopolou E, Brown J, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003; 123: 114-8.


217

Cannas G, Thomas X

iz

iS rl

168) Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65. 169) Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colonystimulating factor. Blood 1995; 85: 1655-8. 170) Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-72. 171) Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versusleukemia effect of donor lymphocytes marrow grafted patients. Blood 1995; 86: 2041-50. 172) Edelson R, Berger C, Gasparro F. Treatment of cutaneous T-cell lymphoma by extracorporal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303. 173) Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLAidentical sibling. N Engl J Med 1989; 321: 1174-8. 174) Gluckman E. History of cord blood transplantation. Bone Marrow Transplant 2009; 44: 621-6. 175) Reiffers J, Bernard P, David B, et al. Successful autologous transplantation with peripheral blood hematopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-5. 176) Goldberg SL, Mangan KF, Klumpp TR, et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 1995; 4: 85-90. 177) Richman CM, Weiner RS, Yankee RA. Increasing circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9. 178) To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating haematopoietic stem cells in the very early remission of acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984; 58: 399-410. 179) Socinski MA, Cannistra SA, Elias A, et al. Granulocytemacrophage colony stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-8. 180) Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-81. 181) Haas R, Hohaus S, Egerer G, et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459-65. 182) Sutherland HJ, Eaves CJ, Landsdorp PM, et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83: 3808-14. 183) Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocytemacrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82. 184) Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colonystimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014; 164: 113-23. 185) Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.

©

SI M

TI

Se

rv

hematopoietic stem cells in the peripheral blood of baboons by cross circulation. Blood 1977; 50: 537-42. 150) Goodman JW, Hogdson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702-14. 151) Cavins JA, Scheer SC, Thomas ED, Ferrebee JW. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at –80°C. Blood 1964; 23: 38-42. 152) Storb R, Epstein RB, Ragde H, et al. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 1967; 30: 805-11. 153) Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res 1965; 25: 1516-20. 154) McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171: 293-4. 155) Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-7. 156) Fliedner TM, Körbling M, Calvo W, et al. Cryopreservation of blood mononuclear leukocytes and stem cells suspended in a large fluid volume. A preclinical model for a blood stem cell bank. Blut 1977; 35: 195-202. 157) Goldman JM, Catovsky D, Hows J, et al. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocyte leukemia in transformation. Br J Med 1979; 1: 1310-3. 158) Levin RH, Whang J, Tjio JH, et al. Persistent mitosis of transfused homologous leukocytes in children receiving antileukemic therapy. Science 1963; 142: 1305-11. 159) Körbling M, Dörken B, Ho AD, et al. Autologous transplantation of blood derived hematopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32. 160) Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4. 161) Matsunaga T, Sakamaki S, Kohgo Y, et al. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993; 11: 103-8. 162) Kessinger A, Smith DM, Strandjord SE, et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-6. 163) Russell NH, Hunter A, Rogers S, et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482. 164) Dreger P, Suttorp M, Haferlach T, et al. Allogeneic granulocyte colony stimulating factor mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-7. 165) Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-4. 166) Link H, Arseniev L, Bähre O, et al. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903-9. 167) MacKinnon S, Papadapoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versusleukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-8.




rv

iz

iS rl

207) Sarngadharan MG, Popovic M, Bruch L, et al. Antibodies reactive with a human T-lymphotropic retrovirus (HTLVIII) in the serum of patients with AIDS. Science 1984; 224: 506-8. 208) Ammann JA, Cowan MJ, Wara DW, et al. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet 1983; 1: 956-8. 209) Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med 1984; 310: 69-75. 210) Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. ASH 50th anniversary review. Blood 2008; 112: 2617-26. 211) Stoto MA. The precautionary principle and emerging biologic risks: lessons from human immunodeficiency virus in blood products. Semin Hematol 2006; 43 (Suppl 3): S10-2. 212) Yap PL, Leaver HA, Gillon J. Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 1998; 74 (Suppl 2): 131-4. 213) Brown P. Creutzfelt-Jakob disease : reflections on risk from blood product therapy. Haemophilia 2007; 13 (Suppl 5): 32-9. 214) Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transf Med Rev 2008; 22: 58-69. 215) Vamvakas EC. Universal white blood cell reduction in Europe: has transmission of variant Creutzfeldt-Jakob disease been prevented? Transfus Med Rev 2011; 25: 133-44. 216) Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33: 721-6. 217) Brittingham TE. Immunologic studies on leukocytes. Vox Sang 1957; 2: 242-8. 218) Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25: 573-7. 219) Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49: 2743-58. 220) Ley TJ, Griffith P, Nienhuis AW. Transfusion haemosiderosis and chelation therapy. Clin Haematol 1982; 11: 437-64. 221) Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007; 21: 327-48. 222) Graw RG, Buckner CD, Whang-Peng J, et al. Complication of bone-marrow transplantation. Graft-versus-host disease resulting from chronic-myelogenous-leukaemia leucocyte transfusions. Lancet 1970; 2: 338. 223) Klein HG. Transfusion-associated graft-versus-host disease: less fresh blood and more gray (Gy) for an aging population. Transfusion 2006; 46: 878-80. 224) Greenwalt TJ, Gajewski M, McKenna JL. A new method for preparing buffy coat-poor blood. Transfusion 1962; 2: 221-4. 225) Luban NLC. Advances in transfusion medicine. In: American Society of Hematology: 50 Years in Hematology: Research that Revolutionized Patient Care. Washington: ASH; 2008. p. 8-9. 226) Rooney CM, Heslop HE, Bremner MK. EBV-specific CTL: a model for immune therapy. Vox Sang 1998; 74 (Suppl 2): 497-9. 227) Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-8. 228) Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 2008; 21: 405-20. 229) Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces

©

SI M

TI

Se

186) Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-73. 187) Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colonystimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300. 188) Elliot BC, Samson DM, Armitage S, et al. When to harvest peripheral blood stem cells after mobilization therapy: prediction of CD34+ cell yield by preceding day CD34+ concentration in peripheral blood. J Clin Oncol 1996; 14: 970-3. 189) Bandarenko N, Sims L, Brecher M. Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields. Transfusion 1997; 37: 1218. 190) Lee JH, Klein HG. Collection and use of circulating hematopoietic progenitor cells. Hematol Oncol Clin North Am 1995; 9: 1-22. 191) Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-17. 192) Ness PM, Campbell-Lee SA. Single-donor versus pooled random-donor platelet concentrates. Curr Opin Hematol 2001; 8: 392-6. 193) Wagner SJ, Maroff G, Katz AJ, Friedman LI. Comparison of bacterial growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion 1995; 35: 298-303. 194) Sneader W. Drug Discovery: A History. New York: John Wiley and Sons; 2005. p. 356-7. 195) Kilduffe RA, DeBakey M. The Blood Bank and the Techniques and Therapeutics of Transfusion. St Louis: Mosby; 1942. 196) Pittman M. A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med 1953; 42: 273-88. 197) Kuehnert MJ, Roth VR, Haley NR, et al. Transfusiontransmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 1493-9. 198) Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006; 46: 719-30. 199) Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41: 857-61. 200) Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. JAMA 1943; 121: 1332-4. 201) Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-31. 202) Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-6. 203) Bradley DW, Balayan MS. Virus of enterically transmitted non-A, non-B hepatitis. Lancet 1988; 1: 819. 204) Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62. 205) Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71. 206) Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of a cytopathic retrovirus (HTLVIII) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500-3.


219

Cannas G, Thomas X

iz

iS rl

249) Hustin A. Principe d'une nouvelle méthode de transfusion. Journal de Médecine (Brussels) 1914; 2: 436 [In French]. 250) Agote L. Nuevo procediemento para la transfusion del sangre. An Inst Mod Clin Med Buenos Aires 1915; 2: 24-30 [In Spanish]. 251) Lewisohn R. Effects of sodium citrate on blood coagulation. Ann Surg 1922; 76: 547-8. 252) Lewisohn R. A new and greatly simplified method of blood transfusion. Med Reconciliation 1915; 87: 141-2. 253) Duran Jorda F. The Barcelona Blood Service. Lancet 1939; 1: 773-5. 254) Flosdorf EW, Mudd S. Procedure and apparatus for preservation in "lyophile" form of serum and other biological substances. J Immunol 1935; 29: 389-425. 255) Coombs RRA, Mourant AE, Race RR. Detection of weak and "incomplete" Rh agglutinins: a new test. Lancet 1945; 2: 15. 256) Kekwick RA, Mackay ME, Record BR. The fractionation of human plasma with ether. Nature 1946; 157: 629. 257) Walter CW, Murphy WP. A closed gravity technique for the preservation of whole blood in ACD solution utilising plastic equipment. Surg Gynecol Obstet 1952; 94: 687-92. 258) Gibson JG II, Sack T, Buckley ES Jr. The preservation of whole ACD blood, collected, stored and transfused in plastic equipment. Surg Gynecol Obstet 1952; 95: 113-9. 259) Dausset J. Iso-leuko-anticorps. Acta Haemat 1958; 20: 156-66. 260) Beutler A, West C. The storage of hard-packed red blood cells in citrate-phosphate-dextrose (CPD) and CPD-adenine (CPDA-1). Blood 1979; 54: 280-4.

©

SI M

TI

Se

rv

T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-9. 230) Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilm's tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824-9. 231) Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-34. 232) Ly LV, Sluijter M, Versluis M, et al. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010; 70: 8339-46. 233) Mc Kenna DH Jr, Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47: 520-8. 234) Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adaptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7. 235) Castiello L, Sabatino M, Jin P, et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother 2011; 60: 457-66. 236) Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16: 336-41. 237) Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116: 3875-86. 238) Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-102. 239) Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305-15. 240) Leacock JH. On the Transfusion of Blood in Extreme Cases of Haemorrhage (dissertation). University of Edinburgh; 1816. 241) Blundell J. Experiments on the transfusion of blood by a syringe. Med Chir Trans 1818; 9: 56-92. 242) Jones HW, Mackmull G. The influence of James Blundell on the development of blood transfusion. Ann Med History 1928; 10: 242-8. 243) Blundell J. Some account of a case of obstinate vomiting in which an attempt was made to prolong life by the injection of blood into the veins. Med Chir Transact 1819; 10: 296-311. 244) Smith T. Transfusion of blood. Lancet 1873; 101: 837-8. 245) Learoyd P. The history of blood transfusion prior to the 20th century - part 2. Transf Med 2012; 22: 372-6. 246) Howe JW. Transfusion of goat's milk. NY State J Med 1875; 21: 506-8. 247) Thomas TG. The intravenous injection of milk as a substitute for the transfusion of blood. NY State J Med 1878; 27: 449-65. 248) Hayem G. Des injections salines intra-veineuses. In: Carré G, Naud C, editors. Paris; 1896 [In French].

Arrived: 23 March 2014 - Revision accepted: 24 June 2014 Correspondence: Xavier Thomas Hospice Civils de Lyon - Lyon-Sud Hospital Haematology Department Pavillon Marcel Bérard - Bat. 1G 69495 Pierre Bénite cedex, France e-mail: [email protected]



Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.

Alveolar bone loss in patients with long-term supportive care.

Historical perspectives.

Postinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?

Overview and Historical Perspectives.

Postanesthetic delirium: historical perspectives.

Acute leukaemia with eosinophilia or acute eosinophilic leukaemia: a dilemma.

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.

Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Hepatitis C infection in multitransfused patients with acute leukaemia.

Leukaemia-associated antigen in serum of patients with acute lymphoblastic leukaemia.

Auer bodies in acute myeloid leukaemia patients.

Challenges in supportive cancer care: perspectives from the Asia Pacific and Middle East.

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.

Patients' and parents' views regarding supportive care in childhood cancer.

Autoimmune Bullous Diseases: Historical Perspectives.

The changing paradigm for supportive care in cancer patients.

Basophils: historical reflections and perspectives.

Historical Perspectives on Flavivirus Research.

Historical perspectives of collagen diseases.

Sudden cardiac death--historical perspectives.

Supportive care in marrow transplantation.

Patient Perspectives on Accessing Acute Illness Care.

Supportive care guidelines.